This is the authors' abstract. We don't add key points for this paper.
Teplizumab delayed progression to clinical type 1 diabetes in high-risk participants. (Funded by the National Institutes of Health and others; ClinicalTrials.gov number, NCT01030861.).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Herold et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: